drugset / Trial / NCT00103142

Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer

NCT00103142

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells. Biological therapies, such as Granulocyte-macrophage colony-stimulating factor (GM-CSF), may stimulate the immune system in different ways and stop tumor cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: This randomized phase II trial is studying giving vaccine therapy together with dendritic cells to see how well it works compared to giving vaccine therapy together with GM-CSF in treating patients with liver or lung metastases from colorectal cancer removed by surgery.

Timeline

Start
2005-02
Primary completion
2009-06
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Falimarev Vaccine Subcutaneous
Subject Inalimarev Vaccine Subcutaneous
Subject sargramostim Protein / enzyme biologic Subcutaneous
Subject therapeutic autologous dendritic cells Vaccine Subcutaneous